ArticleDrug design, development and therapy2022

Risk Factors for Hepatic Encephalopathy in Hepatocellular Carcinoma After Sorafenib or Lenvatinib Treatment: A Real-World Study.

Bowen Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.